First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment.
In prolactin-secreting giant adenomas, cabergoline treatment is the first line approach. Surgery and/or radiotherapy are indicated when the tumour is resistant to medical treatment and continues growing, causing visual field impairment. Data concerning other therapeutic approach are scanty. Although PRL-secreting tumours may express somatostatin receptors type 2, 3 and 5, somatostatin analogs treatment is generally ineffective and peptide receptor radionuclide therapy (PRRT) has never been reported. A 58 year-old woman complaining of severe neurological symptoms caused by a giant prolactinoma, relapsing after surgery and not-responding to dopamine-agonists and octreotide LAR treatment, underwent four cycles of PRRT with 111-Indium-DTPA-octreotide with remarkable tumour shrinkage and a significant improvement in clinical conditions. No side effects were reported. This is the first report on the effectiveness and safety of PRRT with radio-labelled somatostatin analogs in a patient with aggressive giant prolactinoma resistant to conventional treatment.
Department of Radiological Sciences, Unit of Nuclear Medicine, University of Messina, Messina, Italy.
S
S
Baldari
F
F
Ferraù
C
C
Alafaci
A
A
Herberg
F
F
Granata
V
V
Militano
F M
FM
Salpietro
F
F
Trimarchi
S
S
Cannavò
D005260:Female; D006801:Humans; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015175:Prolactinoma / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D011877:Radionuclide Imaging
C094279:indium-111-octreotide; D015282:Octreotide